News Clinuvel Pharmaceuticals Limited

Equities

CUV

AU000000CUV3

Delayed Australian S.E. Other stock markets 01:59:28 2024-04-18 am EDT			5-day change	1st Jan Change
15.27 ^AUD	+0.79%		-0.20%	-4.69%

Mar. 14	Clinuvel Pharmaceuticals Launches Share Buyback Program	MT
Mar. 14	Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors	Mar. 28	AQ
Clinuvel Pharmaceuticals Launches Share Buyback Program	Mar. 14	MT
Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16	Mar. 13	MT
Clinuvel Pharmaceuticals Limited announces an Equity Buyback for 1,500,000 shares, representing 2.99% of its issued share capital.	Mar. 13	CI
Clinuvel Pharmaceuticals Limited authorizes a Buyback Plan.	Mar. 13	CI
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine	Mar. 04	AQ
Clinuvel Reports Positive Results in SCENESSE Study	Mar. 03	MT
Transcript : Clinuvel Pharmaceuticals Limited, H1 2024 Earnings Call, Feb 22, 2024	Feb. 22
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 21	CI
Clinuvel Pharmaceuticals Limited Announces Change to Registered Office	Dec. 06	CI
Clinuvel Doses First Patient in Phase 3 Trial of Vitiligo Treatment	23-10-18	MT
Transcript : Clinuvel Pharmaceuticals Limited - Special Call	23-10-01
Clinuvel Pharmaceuticals Limited Announces Board Changes	23-09-28	CI
Clinuvel Pharmaceuticals Teams Up With Vitiligo Experts to Assess Scenesse	23-09-13	MT
Ex-dividend day for final dividend	23-09-04	FA
Transcript : Clinuvel Pharmaceuticals Limited, 2023 Earnings Call, Aug 29, 2023	23-08-29
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023	23-08-28	CI
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI
Clinuvel Pharmaceuticals Secures Supply Contract for Porphyria Medication with the US Department of Veterans Affairs	23-07-26	MT
Clinuvel Pharmaceuticals Secures Patents for Melanocortins for Treatment of Central Nervous System Disorders	23-07-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Clinuvel Pharmaceuticals Limited

Equities

CUV

AU000000CUV3

Summary

Filters